CA2845127A1 - Compose de pyrazole et utilisation pharmaceutique pour l'inhibition de sglt1 - Google Patents

Compose de pyrazole et utilisation pharmaceutique pour l'inhibition de sglt1 Download PDF

Info

Publication number
CA2845127A1
CA2845127A1 CA2845127A CA2845127A CA2845127A1 CA 2845127 A1 CA2845127 A1 CA 2845127A1 CA 2845127 A CA2845127 A CA 2845127A CA 2845127 A CA2845127 A CA 2845127A CA 2845127 A1 CA2845127 A1 CA 2845127A1
Authority
CA
Canada
Prior art keywords
group
compound
alkyl group
alkoxy
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2845127A
Other languages
English (en)
Other versions
CA2845127C (fr
Inventor
Tomoya Miura
Yosuke Ogoshi
Kazuhito Ueyama
Dai Motoda
Toshihiko IWAYAMA
Koichi Suzawa
Hironobu Nagamori
Hiroshi Ueno
Akihiko Takahashi
Kazuyuki Sugimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CA2845127A1 publication Critical patent/CA2845127A1/fr
Application granted granted Critical
Publication of CA2845127C publication Critical patent/CA2845127C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un composé de formule générale [Ib], ou un sel pharmaceutiquement acceptable de celui-ci. [Dans la formule, chaque symbole est tel que défini dans la description.]
CA2845127A 2011-08-31 2012-08-30 Compose de pyrazole et utilisation pharmaceutique pour l'inhibition de sglt1 Active CA2845127C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011-188121 2011-08-31
JP2011188121 2011-08-31
US201161573433P 2011-09-06 2011-09-06
US61/573433 2011-09-06
PCT/JP2012/072066 WO2013031922A1 (fr) 2011-08-31 2012-08-30 Composé pyrazolique et son utilisation à des fins médicales

Publications (2)

Publication Number Publication Date
CA2845127A1 true CA2845127A1 (fr) 2013-03-07
CA2845127C CA2845127C (fr) 2020-03-10

Family

ID=47756400

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2845127A Active CA2845127C (fr) 2011-08-31 2012-08-30 Compose de pyrazole et utilisation pharmaceutique pour l'inhibition de sglt1

Country Status (28)

Country Link
US (5) US8846746B2 (fr)
EP (4) EP3199533B1 (fr)
JP (6) JP6091811B2 (fr)
KR (1) KR101989203B1 (fr)
CN (1) CN103917535B (fr)
AR (2) AR087701A1 (fr)
AU (1) AU2012302723B2 (fr)
BR (1) BR112014004651B1 (fr)
CA (1) CA2845127C (fr)
CL (1) CL2014000490A1 (fr)
CO (1) CO6890098A2 (fr)
CY (1) CY1121631T1 (fr)
DK (1) DK3199533T3 (fr)
HK (1) HK1202290A1 (fr)
IL (1) IL230763A (fr)
MX (1) MX359825B (fr)
MY (1) MY172422A (fr)
PE (1) PE20142343A1 (fr)
PH (1) PH12014500444A1 (fr)
PL (1) PL3199533T3 (fr)
RS (1) RS58870B1 (fr)
RU (1) RU2617678C2 (fr)
SG (1) SG11201400244YA (fr)
SI (1) SI3199533T1 (fr)
SM (1) SMT201900292T1 (fr)
TW (1) TWI549949B (fr)
WO (1) WO2013031922A1 (fr)
ZA (1) ZA201401071B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230210831A1 (en) * 2019-09-04 2023-07-06 Japan Tobacco Inc. Chronic kidney disease treatment or prevention method

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
US9273085B2 (en) 2012-05-07 2016-03-01 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative and use thereof for medical purposes
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
CN104955481B (zh) * 2013-02-04 2017-10-24 大正制药株式会社 便秘症的预防或治疗药
US9334307B2 (en) 2013-05-08 2016-05-10 The University Of Houston System Targeting the EGFR-SGLT1 interaction for cancer therapy
CN105294703B (zh) * 2015-10-23 2018-01-23 西安近代化学研究所 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法
EP3497092A1 (fr) 2016-08-11 2019-06-19 Bayer CropScience Aktiengesellschaft Dérivés de pyrazolinyle substitués, procédés de production de ces dérivés et leur utilisation comme herbicides et/ou régulateurs de croissance des plantes
ES2863853T3 (es) 2016-08-15 2021-10-11 Bayer Cropscience Ag Procedimiento para la preparación de 3-amino-1-(2,6-disustituido-fenil)pirazoles
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) * 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途
CN114585387B (zh) * 2019-09-04 2024-10-29 日本烟草产业株式会社 利用联用药物的糖尿病的治疗或预防方法
EP4122495A4 (fr) 2020-03-19 2024-03-27 Japan Tobacco Inc. Méthode de traitement ou de prévention des insuffisances cardiaques chroniques
WO2025249555A1 (fr) * 2024-05-31 2025-12-04 Japan Tobacco Inc. Méthode de traitement ou de prévention de la cardiomyopathie hypertrophique

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
MXPA02001498A (es) * 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
BRPI0313290B1 (pt) * 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
ES2328384T3 (es) 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
WO2007034279A2 (fr) * 2005-09-19 2007-03-29 Pfizer Products Inc. Antagonistes de c3a et leurs compositions pharmaceutiques
JP5069894B2 (ja) * 2005-10-21 2012-11-07 田辺三菱製薬株式会社 ピラゾール化合物
EP1951678A1 (fr) 2005-10-21 2008-08-06 Mitsubishi Tanabe Pharma Corporation Composes pyrazole presentant une activite antagoniste du recepteur cannabinoide (cb1)
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
US20070117858A1 (en) 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
WO2008045484A1 (fr) * 2006-10-10 2008-04-17 Amgen Inc. Composés de n-arylpyrazole à utiliser contre le diabète
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
WO2010048149A2 (fr) 2008-10-20 2010-04-29 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
JP2010222298A (ja) * 2009-03-24 2010-10-07 Shionogi & Co Ltd Ｎｐｙｙ５受容体拮抗作用を有するピロリドン誘導体
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
JP5944823B2 (ja) 2010-07-02 2016-07-05 あすか製薬株式会社 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤
EP2651405A2 (fr) 2010-12-14 2013-10-23 Electrophoretics Limited Inhibiteurs de caséine kinase 1 (ck1 )
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230210831A1 (en) * 2019-09-04 2023-07-06 Japan Tobacco Inc. Chronic kidney disease treatment or prevention method

Also Published As

Publication number Publication date
JP2023087032A (ja) 2023-06-22
MX359825B (es) 2018-10-10
SG11201400244YA (en) 2014-10-30
SMT201900292T1 (it) 2019-07-11
BR112014004651A2 (pt) 2017-03-28
EP2784074A1 (fr) 2014-10-01
CY1121631T1 (el) 2020-07-31
CN103917535B (zh) 2015-06-24
EP3199533B1 (fr) 2019-02-27
PL3199533T3 (pl) 2019-09-30
TW201321372A (zh) 2013-06-01
IL230763A (en) 2016-10-31
CL2014000490A1 (es) 2014-08-22
NZ620977A (en) 2016-02-26
PE20142343A1 (es) 2015-01-29
CA2845127C (fr) 2020-03-10
JP2020125348A (ja) 2020-08-20
IL230763A0 (en) 2014-03-31
ZA201401071B (en) 2016-10-26
US20130085132A1 (en) 2013-04-04
WO2013031922A1 (fr) 2013-03-07
KR101989203B1 (ko) 2019-06-13
JP6091811B2 (ja) 2017-03-08
AR123441A2 (es) 2022-11-30
HK1202290A1 (en) 2015-09-25
CO6890098A2 (es) 2014-03-10
EP2784074A4 (fr) 2015-06-03
US20180346449A1 (en) 2018-12-06
KR20140062048A (ko) 2014-05-22
AR087701A1 (es) 2014-04-09
JP2025039641A (ja) 2025-03-21
JP2017082005A (ja) 2017-05-18
JP2018115216A (ja) 2018-07-26
EP3199533A1 (fr) 2017-08-02
US8846746B2 (en) 2014-09-30
US20230348438A1 (en) 2023-11-02
DK3199533T3 (da) 2019-05-20
US20200317644A1 (en) 2020-10-08
RU2014112048A (ru) 2015-10-10
MY172422A (en) 2019-11-25
TWI549949B (zh) 2016-09-21
EP3524599A1 (fr) 2019-08-14
AU2012302723A1 (en) 2014-02-27
RU2617678C2 (ru) 2017-04-26
PH12014500444A1 (en) 2017-04-07
RS58870B1 (sr) 2019-08-30
AU2012302723B2 (en) 2016-08-11
MX2014002552A (es) 2014-04-25
JP2013063968A (ja) 2013-04-11
BR112014004651B1 (pt) 2021-08-31
CN103917535A (zh) 2014-07-09
US20150183763A1 (en) 2015-07-02
EP4656638A3 (fr) 2026-01-28
EP4656638A2 (fr) 2025-12-03
SI3199533T1 (sl) 2019-06-28

Similar Documents

Publication Publication Date Title
CA2845127C (fr) Compose de pyrazole et utilisation pharmaceutique pour l'inhibition de sglt1
EP3307727B1 (fr) Inhibiteurs hétérocycliques des protéines erk1 et erk2 et leur utilisation dans le traitement du cancer
CA3095451C (fr) Composes ox2r
SG191041A1 (en) Polycyclic lpa1 antagonist and uses thereof
TW202128665A (zh) 使用ｅｒｋ１與ｅｒｋ２之雜環抑制劑之改良之方法、套組、組成物及給藥攝生法
JP2006515003A (ja) 新規なＮ−モノアシル化ｏ−フェニレンジアミン、それらの縮合複素環式誘導体および製剤としてのそれらの使用
TW202222770A (zh) 苄胺或苄醇衍生物及其用途
EP1881975A1 (fr) Dérivés de 3-aminopyrrolidine n,n-substitués pouvant être employés en tant qu'inhibiteurs de la recapture de monoamines
TW202342061A (zh) Ｌｏｎｐ１抑制劑、用途及方法
NZ620977B2 (en) Pyrazole compound and use thereof for medical purposes
HK1242309B (en) Pyrazole compound and pharmaceutical use thereof
HK1242309A1 (en) Pyrazole compound and pharmaceutical use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170821

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702